Inovio Pharmaceuticals (INO) Fundamentals 2026 — Revenue Analysis | SniperIQ

.07 on the NASDAQ. This SniperIQ fundamentals page covers Inovio Pharmaceuticals's valuation, profitability (net margin 0.0%), revenue ($65,343 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Inovio Pharmaceuticals's market cap?

Inovio Pharmaceuticals (INO) has a market capitalization of approximately $57M, trading at

.07 on the NASDAQ. Market cap moves with the live share price.

What is Inovio Pharmaceuticals's P/E ratio?

Inovio Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 121.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Inovio Pharmaceuticals?

Inovio Pharmaceuticals runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Inovio Pharmaceuticals generate?

Inovio Pharmaceuticals reported revenue of $65,343 for fiscal year 2025, with net income of -$85M and earnings per share (EPS) of -1.81. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Inovio Pharmaceuticals pay a dividend?

Inovio Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Inovio Pharmaceuticals financially healthy?

Inovio Pharmaceuticals carries a debt-to-equity ratio of 1.43x and a current ratio of 1.04x, with a market beta of 1.49. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Inovio Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Inovio Pharmaceuticals (INO) the key facts are: market cap $57M, revenue $65,343, 52-week range 1.03-2.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.